严重社区获得性肺炎患者气道分泌物中的曲伐沙星浓度。
Trovafloxacin concentrations in airway fluids of patients with severe community-acquired pneumonia.
作者信息
Peleman R A, Van De Velde V, Germonpré P R, Fleurinck C, Rosseel M T, Pauwels R A
机构信息
Division of Infectious Diseases, Department of Internal Medicine, University Hospital Ghent, 185 De Pintelaan, B9000 Ghent, Belgium.
出版信息
Antimicrob Agents Chemother. 2000 Jan;44(1):178-80. doi: 10.1128/AAC.44.1.178-180.2000.
Abstract
The penetration of trovafloxacin (TVA), 200 mg once daily, into the airways of 17 patients with severe pneumonia was studied. The mean (standard deviations are given in parentheses) steady-state TVA concentrations, 2 h after the last intake, were 3.1 (0.3) mg/liter in induced sputum (n = 8), 3.2 (1.1) mg/liter in bronchial secretions (n = 9), 3.2 (0.9) mg/liter in bronchoalveolar lavage fluid (n = 10), and 4.9 (1.4) mg/liter in epithelial lining fluid (n = 11).
摘要
对17例重症肺炎患者进行研究，观察每日一次服用200毫克曲伐沙星（TVA）后在气道中的渗透情况。末次给药2小时后的平均（括号内为标准差）稳态TVA浓度如下：诱导痰中为3.1（0.3）毫克/升（n = 8），支气管分泌物中为3.2（1.1）毫克/升（n = 9），支气管肺泡灌洗液中为3.2（0.9）毫克/升（n = 10），上皮衬液中为4.9（1.4）毫克/升（n = 11）。
相似文献
1
Trovafloxacin concentrations in airway fluids of patients with severe community-acquired pneumonia.
Antimicrob Agents Chemother. 2000 Jan;44(1):178-80. doi: 10.1128/AAC.44.1.178-180.2000.
2
Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin.
J Antimicrob Chemother. 2001 Nov;48(5):735. doi: 10.1093/jac/48.5.735.
3
A prospective, double-blind, multicenter study comparing clarithromycin extended-release with trovafloxacin in patients with community-acquired pneumonia.
Clin Ther. 2002 Apr;24(4):605-15. doi: 10.1016/s0149-2918(02)85136-0.
4
Concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administration of single or multiple oral doses to patients undergoing fibre-optic bronchoscopy.
J Antimicrob Chemother. 1997 Jun;39(6):797-802. doi: 10.1093/jac/39.6.797.
5
Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin.
J Antimicrob Chemother. 2001 Jul;48(1):67-74. doi: 10.1093/jac/48.1.67.
6
Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia.
Eur J Clin Microbiol Infect Dis. 1998 Jun;17(6):447-53. doi: 10.1007/BF01691581.
7
Ethanol feeding does not affect the efficacy or pharmacokinetics of azithromycin, trovafloxacin, or ceftriaxone in a rat model of pneumococcal pneumonia.
Alcohol Clin Exp Res. 1999 May;23(5):842-9.
8
Population pharmacokinetics of moxifloxacin in plasma and bronchial secretions in patients with severe bronchopneumonia.
Clin Pharmacol Ther. 2003 Oct;74(4):353-63. doi: 10.1016/S0009-9236(03)00201-7.
9
[Pharmacokinetics and safety of trovafloxacin].
Enferm Infecc Microbiol Clin. 1998 Dec;16 Suppl 2:36-42; discussion 47-52.
10
[Use of trovafloxacin therapy in community-acquired pneumonia].
Medicina (B Aires). 1999;59 Suppl 1:31-8.
引用本文的文献
1
Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents.
Clin Pharmacokinet. 2011 Oct;50(10):637-64. doi: 10.2165/11594090-000000000-00000.
2
A critical review of the fluoroquinolones: focus on respiratory infections.
Drugs. 2002;62(1):13-59. doi: 10.2165/00003495-200262010-00002.
本文引用的文献
1
The cellular composition of induced sputum in chronic obstructive pulmonary disease.
Eur Respir J. 1999 Apr;13(4):839-43. doi: 10.1034/j.1399-3003.1999.13d24.x.
2
Trovafloxacin: a new fluoroquinolone.
Ann Pharmacother. 1999 Jan;33(1):48-60. doi: 10.1345/aph.17460.
3
In vitro activity of trovafloxacin (CP 99,219), a new fluoroquinolone against hospital isolates.
Chemotherapy. 1999 Jan-Feb;45(1):22-7. doi: 10.1159/000007161.
4
Methods of examining induced sputum: do differences matter?
Eur Respir J. 1998 Mar;11(3):529-33.
5
Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America.
Clin Infect Dis. 1998 Apr;26(4):811-38. doi: 10.1086/513953.
6
Concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administration of single or multiple oral doses to patients undergoing fibre-optic bronchoscopy.
J Antimicrob Chemother. 1997 Jun;39(6):797-802. doi: 10.1093/jac/39.6.797.
7
In vitro activity and selection of disk content for disk diffusion susceptibility tests with trovafloxacin.
Eur J Clin Microbiol Infect Dis. 1996 Aug;15(8):678-82. doi: 10.1007/BF01691159.
8
Determination of trovafloxacin, a new quinolone antibiotic, in biological samples by reversed-phase high-performance liquid chromatography.
J Chromatogr B Biomed Appl. 1996 Jan 12;675(1):53-9. doi: 10.1016/0378-4347(95)00340-1.
9
In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria.
Antimicrob Agents Chemother. 1993 Feb;37(2):366-70. doi: 10.1128/AAC.37.2.366.
10
In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone.
Antimicrob Agents Chemother. 1993 Feb;37(2):349-53. doi: 10.1128/AAC.37.2.349.
Zotero 插件